MN-001
Liver Fibrosis (NASH)
Key Facts
About MediciNova
MediciNova is a clinical-stage biopharma headquartered in La Jolla, California, with a strategy centered on developing and commercializing novel therapeutics in the U.S. market. The company leverages strategic alliances, primarily with Japanese pharmaceutical partners, to build a diversified portfolio of clinical and preclinical candidates. Its current focus is on advancing its lead programs in neurological disorders, acute respiratory conditions, and fibrotic liver disease, while seeking to monetize other assets at key value inflection points.
View full company profileAbout MediciNova
MediciNova is a clinical-stage biopharma headquartered in La Jolla, California, with a strategy centered on developing and commercializing novel therapeutics in the U.S. market. The company leverages strategic alliances, primarily with Japanese pharmaceutical partners, to build a diversified portfolio of clinical and preclinical candidates. Its current focus is on advancing its lead programs in neurological disorders, acute respiratory conditions, and fibrotic liver disease, while seeking to monetize other assets at key value inflection points.
View full company profileAbout MediciNova
MediciNova is a clinical-stage biopharma headquartered in La Jolla, California, with a strategy centered on developing and commercializing novel therapeutics in the U.S. market. The company leverages strategic alliances, primarily with Japanese pharmaceutical partners, to build a diversified portfolio of clinical and preclinical candidates. Its current focus is on advancing its lead programs in neurological disorders, acute respiratory conditions, and fibrotic liver disease, while seeking to monetize other assets at key value inflection points.
View full company profileAbout MediciNova
MediciNova is a clinical-stage biopharma headquartered in La Jolla, California, with a strategy centered on developing and commercializing novel therapeutics in the U.S. market. The company leverages strategic alliances, primarily with Japanese pharmaceutical partners, to build a diversified portfolio of clinical and preclinical candidates. Its current focus is on advancing its lead programs in neurological disorders, acute respiratory conditions, and fibrotic liver disease, while seeking to monetize other assets at key value inflection points.
View full company profile